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Background/Aims: Interferon-γ-inducible protein 10 (IP-10) 
plays important roles in the pathogenesis of hepatitis C virus 
(HCV) infection. We investigated the association between se-
rum IP-10 levels and liver pathology in patients with chronic 
HCV infection. Methods: The serum IP-10 concentration was 
assessed in 85 patients with chronic HCV infection using a 
solid phase sandwich enzyme-linked immunosorbent assay, 
and a liver biopsy specimen was obtained. The pathology 
was scored using the Knodell histologic activity index (HAI). 
Results: Of the 85 patients, 58 had genotype 1 HCV infec-
tion, 21 had genotype non-1, and 6 were undetermined. The 
serum IP-10 levels did not differ between patients infected 
with genotype 1 and genotype non-1 (p=0.472). In patients 
with genotype 1 infection, the total HAI score and the stage 
of ﬁ  brosis were highly correlated with the serum IP-10 level 
(r=0.555, r=0.578, p<0.001). Furthermore, the serum IP-10 
concentrations of patients with severe ﬁ  brosis (stages 3, 4) 
were higher than those of patients with mild ﬁ  brosis (stages 
0 to 2; 214.4 vs. 72.3 pg/mL, p=0.002) among patients with 
genotype 1 infection. However, in patients without genotype 
1 infection, the histopathology was not associated with the 
serum IP-10 level. A multivariate analysis showed that serum 
IP-10 was an independent predictor of ﬁ  brosis (stages 3, 4) 
in patients with genotype 1 infection (odds ratio, 1.034; 95% 
conﬁ  dence interval, 1.006 to 1.064; p=0.018). Conclusions: 
Serum IP-10 concentration was signiﬁ  cantly correlated with 
the severity of liver histology in genotype 1 HCV infection. (Gut 
Liver 2011;5:506-512)
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INTRODUCTION
The immunological and pathological mechanisms of liver in-
jury caused by the hepatitis C virus (HCV) remain unclear. Sev-
eral reports have suggested that HCV-induced hepatic injuries 
result from the lysis of virus-infected cells by the host immune 
system, T cells and some cytokines, rather than direct destruc-
tion by HCV.
1-3 The host immune response to HCV infection can 
lead to 2 opposite results: spontaneous eradication or chronic 
HCV infection. A powerful and specific cellular response may 
clear HCV, but most patients fail to eradicate HCV and become 
chronically infected with the virus. Persistent HCV infection 
results in chronic inflammation and fibrosis of the liver, cirrho-
sis, and hepatocellular carcinoma. Of the patients with chronic 
HCV infection, 20% progress to cirrhosis and approximately 4% 
progress to hepatocellular carcinoma.
Chemokines are relatively small cytokines that play various 
roles under physiological and pathological conditions. They 
are involved in the immune response, tumor development and 
progression, and tissue regeneration.
4 Chemokines are divided 
into 4 families according to 2 characteristic N-terminal cysteine 
residues: CC, CXC, CX3C, and C.
5 Chemokine receptors are ex-
pressed mainly in leukocytes, and the interaction of chemokines 
with their receptors induces leukocyte migration and activation.
Many chemokines and chemokine receptors are involved in 
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non-EXR (Glu–Leu–Arg)-CXC chemokines and CC chemokines 
may be particularly important in the pathogenesis of HCV infec-
tion.
5-8 For example, the mRNA of CXCL9, CXCL10 (IP-10), and 
CXCL11, which are non-EXR-CXC chemokines, and the mRNA 
of their receptor CXCR3 are highly expressed in HCV infec-
tion.
9,10 In addition, the mRNA expression of CCL2, CCL3, and 
CCL5, which are CC chemokines, and their receptors, CCR2 and 
CCR5, are elevated in HCV infection.
9-11 CXCR3 is expressed on 
activated T and natural killer (NK) cells, and CCR5 is expressed 
on activated memory T cells.
6 Interferon-γ-inducible protein-10 
kDa (IP-10/CXCL10) is a non-EXR-CXC chemokine
12,13 and 
is a chemo-attractant for T lymphocytes, monocytes, and NK 
cells.
14,15 Recently, it was found that the expression of IP-10 
in liver specimens from patients with chronic hepatitis C was 
higher than in patients with chronic hepatitis B and normal 
healthy controls.
16 Furthermore, the expression of IP-10 mRNA 
by hepatocytes strongly correlated with the serum IP-10 levels.
17 
These studies suggest that IP-10 may be involved in the im-
mune response to chronic hepatitis C. In this study, we evalu-
ated the possible association between serum IP-10 levels and 
liver histology in terms of inflammation and fibrosis to examine 
the role of IP-10 in patients with chronic hepatitis C.
MATERIALS AND METHODS
1. Patients
Eighty-five patients with chronic hepatitis C were enrolled 
in this study. All of the patients were adults (median age, 52 
years; range, 26 to 77 years), and consisted of 43 men and 42 
women. The diagnosis of chronic hepatitis C was based on sero-
positivity for anti-HCV antibody using third-generation enzyme 
immunoassay, the confirmation of HCV-RNA using reverse 
transcription-polymerase chain reaction (RT-PCR), and the his-
tology of liver biopsy specimens. Patients with a history of al-
cohol abuse (more than 60 g/day) or taking herbal medicine and 
those diagnosed with hepatic failure (hepatic encephalopathy 
within 3 months after onset of jaundice), decompensated cirrho-
sis, hepatocellular carcinoma, other malignant tumors, or severe 
systemic diseases were excluded from the study. In addition, 
patients were excluded if they had taken immunosuppressants 
within the previous 6 months. The baseline characteristics of the 
patients are listed in Table 1.
2. Laboratory tests and HCV-RNA quantiﬁ  cation
Within 2 weeks before the liver biopsy, HCV-RNA quantifica-
tion and other laboratory tests, including liver function tests, 
were conducted. HCV-RNA titer was determined using RT-PCR 
hybridization (lower limit 1.62×10
3 copies/mL).
3. Liver biopsy
Liver biopsy tissue was obtained from all patients with an 
ultrasound-guided percutaneous approach. An experienced pa-
thologist evaluated and scored the biopsy specimens according 
to the Knodell histologic activity index (HAI). The Knodell HAI 
score (0 to 22 points) consists of grade of inflammation and 
necrosis (range 0 to 18: piecemeal necrosis, 0 to 10; intralobular 
degeneration, 0 to 4; and portal inflammation, 0 to 4) and stage 
of fibrosis (range 0 to 4: no fibrosis, 0; portal fibrosis, 1; peri-
portal fibrosis, 2; septal fibrosis, 3; cirrhosis, 4). The degree of 
fibrosis was classified into mild (stages 0 to 2) and severe (stages 
3, 4) fibrosis.
Table 1. Baseline Characteristics of the Patients
Characteristic Value
No. of patients 85
Mean age, yr*     51.5±11.2 (26–77)
Gender, M/F 43/42
HCV genotype
Genotype 1 58
Genotype non-1 21
Undetermined  6
HCV-RNA titer, log copies/mL  6.3±0.7 (3.3–7.8)
AST, IU/L  79.2±54.0 (19–314)
ALT, IU/L  124.7±101.3 (12–492)
Albumin, g/dL 4.0±0.4
Pathologic findings
Knodell histologic activity index 5.9±3.2 (0–14)
Mean grade 4.1±2.3 (0–11)
Mean stage 1.8±1.2 (0–4)
Median serum IP-10 level, pg/mL  103.8 (3.1–939.5)
Data are presented as mean±SD (range).
HCV, hepatitis C virus; AST, aspartate transaminase; ALT, alanine 
transaminase; IP-10, interferon-γ-inducible protein 10.
Fig. 1. Serum interferon-γ-inducible protein 10 (IP-10) concentrations 
did not differ significantly between patients with genotype 1 (n=58) 
and those without genotype 1 (n=21).508  Gut and Liver, Vol. 5, No. 4, December 2011
4. IP-10 quantiﬁ  cation
Serum samples for IP-10 quantification were obtained on the 
day of the liver biopsy and then stored at –70
oC until analysis. 
The level of secreted IP-10 was measured using a DuoSet ELISA 
Development kit (R&D Systems, Minneapolis, MN, USA) accord-
ing to the manufacturer’s protocol. 
5. Statistical analyses
The Spearman rank test was used to analyze the correlations 
between serum IP-10 levels and histopathology, HCV-RNA titer, 
and laboratory results. Logistic regression was used in univari-
ate and multivariate analyses to determine factors related to 
severe fibrosis. p-values of less than 0.05 were deemed to be 
significant. All statistical analyses were conducted using SPSS 
version 14.0 for Windows (SPSS Inc., Chicago, IL, USA).
RESULTS
The median serum IP-10 level for the 85 patients was 
103.8 pg/mL (range, 3.1 to 939.5). The serum IP-10 level was 
not related to age (≤50 years vs. >50 years, 132.1±182.9 
Fig. 2. The serum interferon-γ-inducible protein 10 (IP-10) concentra-
tion positively correlated with histopathological severity in patients 
with genotype 1 hepatitis C virus infection. 
HAI, histologic activity index.
Fig. 3. The correlations between serum interferon-γ-inducible protein 10 (IP-10) concentration and histopathological findings in patients with 
genotype 1 hepatitis C virus infection: piecemeal necrosis (A), intralobular degeneration (B), portal inflammation (C), and fibrosis (D). In patients 
with genotype 1 HCV infection, the serum IP-10 concentration was significantly correlated with the scores for piecemeal necrosis, portal inflam-
mation, and fibrosis (A, C, and D).You CR, et al: Serum IP-10 in Hepatitis C Virus Infection  509
vs. 116.4±76.8 pg/mL, p=0.587) or gender (male vs. female, 
134.8±163.3 vs. 110.3±81.3 pg/mL, p=0.386). 
1. Genotype of HCV and HCV RNA
Of the 85 patients, 58 had genotype 1 HCV infection, 21 had 
non-1 genotypes, and 6 were undetermined. Serum IP-10 levels 
were similar in HCV patients with genotype 1 and non-1 infec-
tions (130.2±148.5 vs. 105.6±76.7 pg/mL, p=0.472, Fig. 1). The 
mean HCV-RNA titer was 6.3±0.7 log copies/mL (range, 3.3 to 
7.8 log copies/mL). The HCV-RNA titer did not correlate with 
serum IP-10 levels (r=0.063; p=0.579).
2. Association between histological severity and serum IP-
10 level in genotype 1
For the 58 patients with HCV genotype 1, a positive correla-
tion between serum IP-10 concentration and the Knodell HAI 
score was identified (r=0.555, p<0.001, Fig. 2). In terms of the 
relationship between the grade of necroinflammation and the 
serum IP-10 concentration in genotype 1 patients, the serum 
IP-10 concentration correlated with the degree of piecemeal 
necrosis (r=0.416, p=0.001) and portal inflammation (r=0.381, 
p=0.004), but not intralobular degeneration (r=0.060, p=0.660, 
Fig. 3). There was also a significant correlation between the 
serum IP-10 concentration and the stage of fibrosis (r=0.577, 
p<0.001, Fig. 3).
Of the patients infected with HCV genotype 1, the serum IP-
10 concentration in the patients with severe fibrosis (stages 3, 4) 
was significantly higher than in the patients with mild fibrosis 
(stages 0 to 2, 214.4 vs. 72.3 pg/mL, p=0.002, Fig. 4). The re-
ceiver operating characteristic (ROC) curve for severe fibrosis in 
genotype 1-infected patients had an area under the curve (AUC) 
of 0.846 (95% confidence interval [CI], 0.740 to 0.952, Fig. 5). 
Fig. 4. The serum interferon-γ-inducible protein 10 (IP-10) concen-
trations were higher in patients with severe fibrosis (stages 3, 4) than 
in patients with mild fibrosis (stages 0 to 2, 214.4 vs 72.3 pg/mL, 
p=0.002).
Fig. 5. The receiver operating characteristic (ROC) curve of the serum 
interferon-γ-inducible protein 10 (IP-10) concentrations in patients 
with genotype 1 infection and severe fibrosis (stages 3, 4). The area 
under the curve (AUC) was 0.846 (95% confidence interval, 0.740 to 
0.952), and the cutoff value of the serum IP-10 concentration was 
100.3 pg/mL (sensitivity, 82.6%; specificity, 72.7%).
Table 2. Factors Related to Severe Fibrosis in Genotype 1 HCV Infection
Parameter
Univariate analysis Multivariate analysis
OR (95% CI) p-value OR (95% CI) p-value
Age 1.03 (0.99–1.08) 0.185 1.16 (0.94–1.44) 0.170
Gender 1.48 (0.51–4.32) 0.473
Viral load 0.33 (0.11–1.05) 0.060 0.88 (0.10–8.03) 0.913
Serum IP-10 level 1.02 (1.01–1.03) <0.001 1.03 (1.00–1.06) 0.018
AST 1.04 (1.02–1.06) <0.001 1.03 (0.96–1.11) 0.356
ALT 1.01 (1.00–1.02) 0.009 1.02 (0.98–1.07) 0.244
Serum albumin 0.03 (0.00–0.31) 0.004 0.09 (0.00–8.46) 0.301
Total bilirubin 0.71 (0.30–1.70) 0.440
PT INR 5.5×10
6 (248–1.2×10
11) 0.002 2.8×10
13 (0.15–5.2×10
27) 0.065
Platelet count 0.99 (0.98–1.00) 0.053 0.98 (0.94–1.02) 0.297
HCV, hepatitis C virus; OR, odds ratio; CI, confidence interval; IP-10, interferon-γ-inducible protein 10; AST, aspartate transaminase; ALT, alanine 
transaminase; PT INR, prothrombin time international normalized ratio.510  Gut and Liver, Vol. 5, No. 4, December 2011
The cutoff serum IP-10 level for severe fibrosis in genotype 
1-infected patients was 100.3 pg/mL (sensitivity 82.6%, specific-
ity 72.7%). In a multivariate analysis of factors related to severe 
fibrosis, the serum IP-10 level was an independent predictor of 
fibrosis in genotype 1-infected patients (odds ratio, 1.034; 95% 
CI, 1.006 to 1.064; p=0.018, Table 2).
In contrast to patients with genotype-1 HCV infection, no 
significant correlation was observed between serum IP-10 
concentrations and Knodell HAI scores in the 21 patients with 
genotype non-1 HCV infection (r=0.034, p=0.883, Fig. 6). The 
serum IP-10 concentration did not correlate with the degree of 
piecemeal necrosis, intralobular degeneration, portal inflamma-
tion, or stage of fibrosis (Fig. 7).
3. Association between liver enzyme and peripheral blood 
mononuclear cell count and serum IP-10 level
In the patients with genotype-1 HCV infection, as the serum 
aspartate aminotransferase (AST) and alanine aminotransferase 
(ALT) levels became elevated, the serum IP-10 concentration 
also increased, and these correlations were statistically signifi-
cant (r=0.463, p<0.001; r=0.484, p<0.001, respectively). The 
Fig. 6. The serum interferon-γ-inducible protein 10 (IP-10) concentra-
tion did not correlate with the severity of pathology in patients with 
genotype non-1 hepatitis C virus infection. 
HAI, histologic activity index.
Fig. 7. The correlations between the serum interferon-γ-inducible protein 10 (IP-10) concentration and pathology findings in patients with geno-
type non-1 hepatitis C virus infection: piecemeal necrosis (A), intralobular degeneration (B), portal inflammation (C), and fibrosis (D). In these 
patients, the serum IP-10 concentration did not correlate with the scores for piecemeal necrosis, intralobular degeneration, portal inflammation, or 
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serum IP-10 concentration of the patients with AST >100 IU/
L was higher than that of the patients with AST ≤100 IU/L 
(median, 155.4 vs. 83.1 pg/mL, p=0.048). A similar result was 
obtained for the serum ALT (median, 140.8 vs. 80.5 pg/mL, 
p=0.014). A slightly positive (statistically nonsignificant) cor-
relation was observed between the peripheral lymphocyte count 
and serum IP-10 concentration (r=0.250, p=0.058). 
In patients with genotype non-1 HCV infection, serum IP-10 
concentrations did not correlate with the peripheral lymphocyte 
count (r=0.117, p=0.615) or with serum AST (r=0.402, p=0.071) 
or ALT (r=0.233, p=0.308) levels.  
DISCUSSION
IP-10 is a CXC chemokine. Unlike other CXC chemokines, 
IP-10 lacks chemotactic activity for neutrophils, but instead 
targets T lymphocytes, NK cells, and monocytes.
14,15,18 Accord-
ing to recent data, the transcription of IP-10 in hepatocytes and 
the expression of the IP-10 receptor CXCR3 on lymphocytes 
infiltrating the liver are increased in patients with chronic HCV 
infection.
11,19 The serum IP-10 levels in patients with HCV infec-
tion are higher than in healthy controls, patients with hepatitis 
B virus infection, and rheumatoid arthritis patients.
16,19 These 
results imply that IP-10 plays an important role in the patho-
genesis of HCV infection. In HCV infection, the inflammatory 
cells that infiltrate the liver are mainly antigen-nonspecific 
T-helper 1 (Th1) lymphocytes.
20,21 These cells secrete cytokines 
such as interferon-gamma (IFN-γ) and IL-2, which activate 
monocytes and macrophages. In other words, Th1 lymphocytes 
initiate a delayed hypersensitivity reaction by producing IFN-γ 
and IL-2.
22-24 This immune reaction results in ongoing tissue 
damage and progressive liver disease. IP-10 is produced by 
hepatocytes
25,26 and recruits stimulated CD4
+ T cells, NK cells, 
and monocytes to the target site, rather than CD8
+ T cells and 
neutrophils.
14,15,18 IP-10 may be involved in the Th1-dominant 
immune response of chronic hepatitis C. 
In our study, the serum IP-10 level correlated with the his-
tological severity of necroinflammation and fibrosis in patients 
with chronic genotype 1 HCV infection. Interestingly, the 
increasing of serum IP-10 level was independently related to 
severe fibrosis in genotype 1-infected patients. Thus, the IP-10 
level is closely related to the progression of fibrosis in chronic 
HCV-mediated disease. A higher concentration of serum IP-
10 may recruit more CD4
+ T cells to the liver, inducing more 
vigorous immune reactions. This is supported by the correla-
tion between the serum IP-10 level and the liver enzyme levels. 
Additionally, our results may indicate a potential association 
between activation of hepatic stellate cells and chemokines. The 
activation of hepatic stellate cells is known to be a key patho-
genic feature of liver cirrhosis. Many cytokines, platelet-derived 
growth factors, and chemokines are involved in the activation 
of hepatic stellate cells.
27 However, whether hepatic stellate 
cells express a specific receptor for IP-10 is unclear. It is a new 
challenge to discover the exact mechanism as to how IP-10 is 
involved in hepatic fibrosis. 
Several other studies have demonstrated the relationships 
between the pathological findings and serum IP-10 levels.
27,28 
Diago et al.
27 suggested that the serum IP-10 levels are higher in 
patients with advanced fibrosis than in those with mild fibrosis 
with chronic HCV infection, and that this relationship is more 
significant for genotype 1. Romero et al.
28 demonstrated a cor-
relation between IP-10 levels and necroinflammatory activity 
and fibrosis stage in patients with chronic hepatitis C. Recently, 
not only serum IP-10, but also intrahepatic IP-10, was reported 
to correlate with hepatic inflammation and fibrosis in chronic 
hepatitis C.
5 Moreover, elevated intrahepatic mRNA expression 
of IP-10 in chronic HCV-infected patients was found to be asso-
ciated with increased necroinflammation and fibrosis.
5 This re-
sult suggests that serum IP-10 levels correlate with intrahepatic 
IP-10 level, as suggested by Mihm et al.
17 The findings of the 
three studies mentioned above are consistent with our results. 
Furthermore, in our study, we evaluated the association between 
serum IP-10 and the severity of histology in patients with geno-
type non-1 HCV infection. The result was that serum IP-10 in 
patients with genotype non-1 HCV infection was not correlated 
with the severity of necroinflammation or fibrosis, in contrast to 
patients with genotype-1 HCV infection. The reason for this dif-
ference remains unclear, but may be attributable to the different 
mechanisms of pathogenesis involved under the 2 conditions. 
Generally, the prognosis of genotype-1 HCV infection is poorer 
than that of genotype non-1 HCV infection. In genotype-1 HCV 
infection, more powerful immune reactions may be induced, 
and IP-10 may be closely related to disease progression. An-
other issue is that we could not completely evaluate and make 
comparisons in terms of the association between serum IP-10 
levels and the histological severity because of the limited num-
ber of patients with genotype non-1 HCV. 
Patients with HCV infection show very diverse progressions 
in terms of hepatic injury. Some patients will only have mild 
inflammation, without fibrosis, despite the long duration of 
HCV infection, whereas others may progress to severe fibrosis 
or decompensated cirrhosis. According to our study, in patients 
with genotype-1 HCV infection, the serum IP-10 level could be 
a potential prognostic marker for fibrosis. 
In conclusion, we showed that the serum IP-10 concentration 
was correlated with the severity of fibrosis and necroinflam-
mation and that a high serum IP-10 level was an independent 
predictor of severe fibrosis in genotype 1 HCV infection. Further 
studies must determine whether IP-10 has the potential to be 
an important factor in the clinical management of patients with 
chronic hepatitis C such as in the development of new therapeu-
tic strategies or the prediction of the prognosis.512  Gut and Liver, Vol. 5, No. 4, December 2011
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